Table 1.
Patient and angiographic baseline characteristics
| All patients (n=302) | GOODCOLL (n=162) | POORCOLL (n=140) | P values | |
| Age | 60±10 | 59±10 | 61±10 | 0.141 |
| Male | 257 (85%) | 138 (85%) | 119 (85%) | 1.000 |
| Diabetes mellitus | 47 (16%) | 17 (11%) | 30 (21%) | 0.011 |
| Hypertension | 128 (42%) | 58 (36%) | 70 (50%) | 0.014 |
| Hyperlipidaemia | 103 (34%) | 57 (35%) | 46 (33%) | 0.716 |
| Current smoker | 153 (51%) | 79 (49%) | 74 (53%) | 0.770 |
| Previous MI | 43 (14%) | 25 (15%) | 18 (13%) | 0.621 |
| Aspirin | 125 (41%) | 66 (41%) | 59 (42%) | 0.331 |
| Clopidogrel | 43 (14%) | 25 (%) | 18 (%) | 0.383 |
| Prasugrel | 4 (1%) | 1 (1%) | 3 (2%) | 0.268 |
| Ticagrelor | 29 (10%) | 11 (7%) | 18 (13%) | 0.131 |
| Coumarine | 1 (0%) | 0 (0%) | 1 (1%) | 0.145 |
| Beta-blocker | 63 (21%) | 30 (%) | 33 (%) | 0.190 |
| ACE inhibitor | 38 (13%) | 17 (10%) | 21 (15%) | 0.163 |
| Calcium-antagonist | 37 (12%) | 16 (%) | 21 (%) | 0.135 |
| ATII blocker | 31 (10%) | 14 (9%) | 17 (12%) | 0.186 |
| Infarct-related artery (IRA) | <0.001 | |||
| RCA | 93 (31%) | 34 (21%) | 59 (42%) | |
| LCX | 73 (24%) | 43 (27%) | 30 (21%) | |
| LAD | 136 (45%) | 85 (53%) | 51 (36%) | |
| TIMI culprit pre-PCI | 0.274 | |||
| 0–1 | 199 (66%) | 102 (63%) | 97 (69%) | |
| 2–3 | 103 (34%) | 60 (37%) | 43 (31%) | |
| Collaterals to IRA | 80 (27%) | 40 (25%) | 40 (29%) | 0.431 |
| GOODCOLL to IRA | 7 (2%) | 3 (2%) | 4 (3%) | 1.000 |
| CTO artery | <0.001 | |||
| RCA | 142 (47%) | 94 (58%) | 48 (34%) | |
| LCX | 85 (28%) | 41 (25%) | 44 (31%) | |
| LAD | 75 (25%) | 27 (17%) | 48 (34%) | |
| TIMI CTO | ||||
| 0–1 | 300 (99%) | 161 (99%) | 139 (99%) | |
| 2 | 2 (1%) | 1 (1%) | 1 (1%) | 1.000 |
| Collateral grade to CTO | – | |||
| 0 | 10 (3%) | – | 10 (7%) | |
| 1 | 130 (43%) | – | 130 (93%) | |
| 2 | 143 (47%) | 143 (88%) | – | |
| 3 | 19 (6%) | 19 (12%) | – | |
| J-CTO score total | 2.2±1.1 | 2.2±1.1 | 2.2±1.2 | 0.813 |
| SYNTAX score | 29.2±9.2 | 28.0±8.7 | 30.6±9.5 | 0.016 |
| LVEF (%) LVEDV (mL) |
41.2±11.8 211±53 |
42.9±10.9 209.0±51.8 |
39.1±12.6 213.2±55.2 |
0.023 0.577 |
| Scar (g) (n = 149) | ||||
| Total | 8.5 (4.7–15.1) | 7.3 (4.2–14.6) | 8.9 (5.4–17.2) | 0.212 |
| Culprit area | 7.1 (3.7–13.9) | 6.1 (3.4–13.2) | 7.8 (4.1–15.3) | 0.175 |
| CTO area | 0.7 (0.1–1.6) | 0.7 (0.2–1.5) | 0.8 (0.1–1.8) | 0.982 |
| Enzymatic infarct size | ||||
| Peak CK-MB post pPCI | 124.5 (41.2–269.5) | 124.5 (34.3–300.0) | 120.8 (51.8–261.5) | 0.640 |
| Peak troponin T post pPCI | 2.8 (0.8–6.0) | 2.5 (0.8–5.8) | 3.1 (0.8–6.4) | 0.432 |
ATII, Angiotensin-II receptor; CK-MB, creatinin kinase-myocardial band; CTO, coronary chronictotal occlusion; GOODCOLL, well-developed collaterals to the CTO; J-CTO, Japan chronic total occlusion; LAD, leftanterior descending artery; LCX, left circumflex artery; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; POORCOLL, poorly developed collaterals to the CTO; pPCI, primary PCI; RCA, rightcoronary artery; TIMI, thrombolysis in myocardial infarction.